Note: Descriptions are shown in the official language in which they were submitted.
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND AZIRIDINE
ANALOGUES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to the semi-synthesis of taxane
intermediates and aziridine analogues, in particular, aziridine analogues of
cephalomannine and baccatin III intermediates, and their conversion to active
antitumor
agents, paclitaxel and docetaxel.
Description of the Prior Art
Docetaxel (1, Taxotere), a semi-synthetic analog, and paclitaxel (2,
Taxol), a complex diterpene isolated from the bark of the Pacific yew tree
(Taxus
brevifolia) are arguably the most outstanding cancer chemotherapeutic
substances
discovered in recent times. While paclitaxel can be obtained from the yew tree
or semi-
synthetically, only the latter option is currently available for the formation
of non-
natural docetaxel. The partial synthesis of this important compound has
generally been
accomplished through esterification of a derivative of the (2R, 3S)
phenylisoserine side
chain with a protected form of 10-deacetylbaccatin III, a comparatively
abundant
natural product also present in the yew tree.
t-BOO1_~ HO O OH
NH O lo 7
Ph' " 0111 13 "'Wq
OH H O
= Ac
HO OBz
TAXOTERE, (1)
Ac0
O OH
Ph 1-11 NH O lo
Ph" ~ 0ni 13 ~aql
OH H O
= Ac
HO OBz
TAXOL, (2)
In Colin's U.S. Pat. No. 4,814,470, it was reported that docetaxel has an
activity
significantly greater than paclitaxel.
Docetaxel and paclitaxel may be prepared semi-synthetically from 10-
deacetylbaccatin III or baccatin III as set forth in U.S. Pat. Nos. 4,924,011
and
4,924,012 or by the reaction of a(3-lactam and a suitably protected 10-
deacetylbaccatin
1
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
III or baccatin III derivative as set forth in U.S. Pat. No.5,175,315. 10-
deacetylbaccatin
III (10-DAB, 3) and Baccatin III (4) can be separated from mixtures extracted
from
natural sources such as the needles, stems, bark or heartwood of numerous
Taxus
species and have the following structures.
HO O OH
7
E-10111 13
"illl
H 0
= Ac
HO OBz
10 DAB, (3)
Ac0 O OH
IU 7
HOIII 13 ll
H 0
= Ac
HO OBz
5 BACC IH, (4)
Although, most of the research towards the semi-synthesis of docetaxel
and paclitaxel has involved 10-deacetylbaccatin III as the starting material,
other
taxanes present in the yew tree, such as 9-dihydro=13-acetylbaccatin III
(9DHB, 5),
present in the Canadian yew (Taxus Canadensis), and cephalomannine (6) have
been
10 collected and identified.
AcO ~OH OH
O lU
H3C" 'Om 13 ' .Uq
H 0
= Ac
HO OBz
9DHB, (5)
AcO O OH
NH O
HI 7
PL 3 13
tH y O
HO B>O' Ac0
CEPHALOMANNINE, (6)
As disclosed in U.S. Pat. Application No. 10/695,416, which application
is assigned to the assignee of the present invention, docetaxel and pacliaxel
may also be
prepared semi-synthetically from 9-dihydro-13-acetylbaccatin III.
Although there have been many advances in the field, there remains a
need for new and improved processes for the preparation of taxane
intermediates and
their conversion to docetaxel and paclitaxel. The present invention addresses
these
needs and provides further related advantages.
2
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
BRIEF SUMMARY OF THE INVENTION
In brief, the present invention relates to the semi-synthesis of novel
taxane intermediates and aziridine analogues, in particular, aziridine
analogues of
cephalomannine and baccatin III intermediates, and their conversion to active
antitumor
agents, paclitaxel and docetaxel.
In a first embodiment, the present invention provides a process for
preparing a taxane comprising the steps of (1) converting cephalomannine to a
taxane
intermediate having the structure:
AcO 0 OR
NHZ O
]0 7
Ph 3 Nuw =. 13 mntl
~R H O
Ac0
HO BzO~
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group, and (2) converting the taxane intermediate to paclitaxel or
docetaxel.
In a more specific embodiment of the foregoing process, the step of
converting cephalomannine to the taxane intermediate further comprises the
steps of (1)
converting cephalomannine to a cephalomannine aziridine analogue having the
structure:
0
Ac0 0 OR
NH O
=' II 10 7
N ~ Zr JL
Ts Ph/ 3~~: \OUu... 13 mm
~DR H O
HO BzO~ Ac0
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group, and (2) converting the cephalomannine aziridine analogue to
the
taxane intermediate.
In an alternate more specific embodiment of the foregoing process, the
step of converting cephalomannine to the taxane intermediate comprises
reacting
cephalomannine with formic acid.
In yet another alternate more specific embodiment, the step of
converting cephalomannine to the taxane intermediate further comprises the
reaction
sequence:
3
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
0
AcO 0 OR
~ NH O 10
7
zPh 3 Oiu = 13 nti
aR : ~ O
HO BzO~ AcO
1
0
AcO 0 OR
NNO O
io 7
Ph 3 OII~= 13 ==nlll
~)R H O
HO Bz Ac0
1
AcO 0 OR
NHNO 0 10
Ph 3 Olln= 13 ==nlil
:OR O
HO BzO~ AcO
f
AcO 0 OR
NHZ O 10
7
/ \ % ~
Ph 3 OII1-= 13 =mll
eR H~O
HO Bz Ac0
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group.
In yet another alternate more specific embodiment, the step of
converting cephalomannine to the taxane intermediate further comprises the
steps of (1)
converting cephalomannine to a cephalomannine epoxide analogue having the
structure:
0
Ac0 O OR
NH 0
I~
~
O F 2, -
Ph 3 : OUm ==. 13 nml
~R =H O
HO Bz0' Acd
4
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group, (2) converting the cephalomannine epoxide analogue to a
cephalomannine azido alcohol analogue having the structure:
N; O
Ac0 0 OR
HO 2'
NH O Ai
Ph 3 oum .. {1R O
HO Bz05 wherein R is at each occurrence independently selected from hydrogen
and a hydroxy-
protecting group, and (3) converting the cephalomannine azido alcohol analogue
to the
taxane intermediate.
In a second embodiment, the present invention provides a process for
preparing a taxane comprising the steps of (1) converting cinnamoyl halide to
a
cinnamoyl halide aziridine intermediate having the structure:
0
Ph
x
N
Ts
wherein X is halogen, (2) reacting the cinnamoyl halide aziridine intermediate
with
protected baccatin III to provide a protected baccatin III aziridine
intermediate having
the structure:
Ac0 0 OR
Pli
O A
N 0
Ts 15 HO B0wherein R is selected from hydrogen and a hydroxy-protecting group,
(3) converting
the protected baccatin III aziridine intermediate to a taxane intermediate
having the
structure:
AcO 0 OR
F Z, Ph b
NH, O A-zn~~ie'
Ac O
HO Bz20 wherein R is selected from hydrogen and a hydroxy-protecting group,
and (4)
converting the taxane intermediate to paclitaxel or docetaxel.
5
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
In a more specific embodiment of the foregoing process X is chloro.
In a third embodiment, the present invention provides a process for
preparing a taxane comprising the steps of (1) converting cinnamoyl halide to
a
cinnamoyl halide aziridine intermediate having the structure:
0
Ph
X
N
Ts
rvherein X is halogen, (2) converting the cimlamoyl halide aziridine
intermediate to an
open chain cinnamoyl halide intermediate having the structure:
NHTs 0
Ph X
OAc
wherein X is halogen, (3) reacting the open chain cinnamoyl halide
intermediate with
protected baccatin III to provide a protected baccatin III intermediate having
the
structure:
AcO 0 OR
NHTs 0 10 7
Ph Oi~m=. 13 mnl
OAc }~ , O
HO BzO~ Ac0
wherein R is selected from hydrogen and a hydroxy-protecting group, (4)
converting
the protected baccatin III intermediate to a taxane intermediate having the
structure:
Ac0 O OR
NH, 0
A-e, bAc O
HO Bzwherein R is selected from hydrogen and a hydroxy-protecting group, and
(5)
converting the taxane intermediate to paclitaxel or docetaxel.
In a more specific embodiment of the foregoing process, the step of
reacting the open chain cinnamoyl halide intermediate with protected baccatin
III
further comprises the steps of (1) converting the open chain cinnamoyl halide
intermediate to a(3-lactam intermediate having the structure:
6
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
AcO Ph
I
O Ts
and (2) reacting the (3-lactam intermediate with protected baccatin III to
provide the
protected baccatin III intermediate.
In another more specific ernbodiment of the foregoing process X is
chloro.
In a fourth embodiment, the present invention provides a process for
preparing docetaxel from cephalomannine comprising the reaction sequence:
O
~x'I Ac0 O OR
7
Ph '' OU~= ~~ =mi
aR ~ H~ O
HO BzO~ Ac0
I
O
Ac0 O OR
N-t-BOC O
lu 7
Ph 3= Olu- ~3 ==m
:eR H~ O
HO BzO~ AcO
I
AcO 0 OR
t-BOC-HN~ O
io 7
Ph = Olu= iz ==ml
i)R } ~ O
HO BzO~ Aco
0 1
HO O OH
t-BuO NH 0 10
11 - 7
- Z
Ph '' Olu = i3 ~nl
O
HO Bz(f AcO
10 wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group.
These and other aspects of the irivention will be apparent upon reference
to the attached figures and following detailed description.
7
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1, 2, 3, 4, 5, 6, 7 and 8 illustrate chemical routes for the
preparation of taxane intermediates and aziridine analogues, and their
conversion to
paclitaxel and docetaxel according to the present invention.
DETAILED DESCRIPTION OF THE INVENTION
As noted above, the present invention relates to the semi-synthesis of
novel taxane intermediates and aziridine analogues, in particular, aziridine
analogues of
cephalomannine and baccatin III intermediates, and their conversion to active
antitumor
agents, paclitaxel and docetaxel.
As used herein, the term "hydroxy-protecting group" refers to a readily
cleavable group bonded to the oxygen of a hydroxy (-OH) group. Examples of
hydroxy
protecting groups include, without limitation, acetyl (Ac), benzyl (PhCH2), 1-
ethoxyethyl (EE), methoxymethyl (MOM), (methoxyethoxy)methyl (MEM), (p-
methoxyphenyl)methoxymethyl (MPM), tert-butyldimethylsilyl (TBS), tert-
butyldiphenylsilyl (TBPS), tert-butoxycarbonyl (tBoc, t-Boc, tBOC, t-BOC),
tetraliydropyranyl (THP), triphenylmethyl (Trityl, Tr), 2-methoxy-2-
methylpropyl,
benzyloxycarbonyl (Cbz), trichloroacetyl (OCCC13), 2,2,2-
trichloroethoxycarbonyl
(Troc), benzyloxymethyl (BOM), tert-butyl (t-Bu), triethylsilyl (TES),
trimethylsilyl
(TMS), and triisopropylsilyl (TIPS). The related term "protected hydroxy
group" refers
to a hydroxy group that is bonded to a hydroxy-protecting group. General
examples of
protected hydroxy groups include, without limitation, -0-alkyl, -O-acyl,
acetal, and -0-
ethoxyethyl, where some specific protected hydroxy groups include, formyloxy,
acetoxy, propionyloxy, chloroacetoxy, bromoacetoxy, dichloroacetoxy,
trichloroacetoxy, trifluoroacetoxy, methoxyacetoxy, phenoxyacetoxy,
benzoyloxy,
benzoylformoxy, p-nitro benzoyloxy, ethoxycarbonyloxy, methoxycarbonyloxy,
propoxycarbonyloxy, 2,2,2-trichloro ethoxycarbonyloxy, benzyloxycarbonyloxy,
tert-
butoxycarbonyloxy, 1-cyclopropyl ethoxycarbonyloxy, phthaloyloxy, butyryloxy,
isobutyryloxy, valeryloxy, isovaleryloxy, oxalyoxy, succinyloxy and
pivaloyloxy,
phenylacetoxy, phenylpropionyloxy, mesyloxy, chlorobenzoyloxy, para-
nitrobenzoyloxy, para-tert-butyl benzoyloxy, capryloyloxy, acryloyloxy,
methylcarbamoyloxy, phenylcarbamoyloxy, naplithylcarbamoyloxy, and the like.
Hydroxy-protecting groups and protected hydroxy groups are described in, e.g.,
C. B.
Reese and E. Haslam, "Protective Groups in Organic Chemistry," J. G. W.
McOmie,
Ed., Plenum Press, New York, N.Y., 1973, Chapters 3 and 4, respectively, and
T. W.
8
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," Second
Edition,
John Wiley and Sons, New York, N.Y., 1991, Chapters 2 and 3.
The following Table shows the chemical structure of some hydroxy-
protecting groups, as well as nomenclature used to identify those chemical
structures.
TABLE 1
Acetyl 0 Acetoxy 0
Ac OAc
( ) H3C-C (' ) H3C-CI
-O
~ ~
Dichloroacetyl I i 11 0 Dichloroacetoxy ( i I I 0 H-C-C-~ H-C-C-O-~
I I
CI CI
Triethylsilyl CH2CH3 Triethylsiloxy CH2CH3
( ) I (- ) I
TES OTES
H3CH2C-Si ~ H3CH2C-Si O ~
I I
CH2CH3 CH2CH3
Benzoyl Benzoyloxy
- oQL Buty j xycarbonyl I CH3 I~ 0
tBOC
H3C- i -O-C
CH3
t-Butoxycarbonyloxy CH3 0
(-O-tBOC) I I I
H3C-C-O-C-O--~
I
CH3
para-Methoxyphenyl
(PMP) H3C-0\ /
The term "alkyl" refers to a hydrocarbon structure wherein the carbons
are arranged in a linear, branched, or cyclic manner, including combinations
thereof.
Lower alkyl refers to alkyl groups of from 1 to 5 carbon atoms. Examples of
lower
alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl
and the like.
"Cycloalkyl" is a subset of alkyl and includes cyclic hydrocarbon groups of
from 3 to
13 carbon atoms. Examples of cycloalkyl groups include cyclopropyl,
cyclobutyl,
cyclopentyl, norbornyl, adamantyl and the like. When an alkyl residue having a
specific number of carbons is named, all geometric isomers having that number
of
9
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
carbons are intended to be encompassed; thus, for example, "butyl" is meant to
include
n-butyl, sec-butyl, isobutyl and t-butyl; propyl includes n-propyl and
isopropyl.
The term "alkenyl" refers to an alkyl group having at least one site of
unsaturation, i.e., at least one double bond.
The term "alkynyl" refers to an alkyl group having at least one triple
bond between adjacent carbon atoms.
The terms "alkoxy" and "alkoxyl" both refer to moieties of the formula
-0-alkyl. Examples include methoxy, ethoxy, propoxy, isopropoxy,
cyclopropyloxy,
cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to
four
carbons. The analogous term "aryloxy" refers to moieties of the formula -0-
aryl.
The term "acyl" refers to moieties of the formula -C(=O)-alkyl. One or
more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur
as long
as the point of attachment to the parent remains at the carbonyl. Examples
include
acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl
and the
like. Lower-acyl refers to groups containing one to four carbons.
The term "aryl" refers to phenyl or naphthyl. Substituted aryl refers to
mono- and poly- substituted phenyl or naphthyl. Exemplary substituents for
aryl
include one or more of halogen, hydroxyl, alkoxy, aryloxy, heteroaryloxy,
amino,
alkylamino, dialkylamino, mercapto, alkylthio, arylthio, heteroarylthio,
cyano,
carboxyl, alkoxycarbonyl where the alkoxy portion contains 1 to 15 carbons,
aryloxycarbonyl where the aryloxy portion contains 6 to 20 carbon, or
heteroarylcarbonyl where the heteroaryl portion contains 3 to 15 carbon atoms.
The term "heteroaryl" refers to a 5- or 6-membered heteroaromatic ring
containing 1-3 heteroatoms selected from 0, N, or S; a bicyclic 9- or 10-
membered
heteroaromatic ring system containing 0-3 heteroatoms selected from 0, N, or
S; or a
tricyclic 13- or 14-membered heteroaromatic ring system containing 0-3
heteroatoms
selected from 0, N, or S. Exemplary aromatic heterocyclic rings include, e.g.,
imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan,
benzimidazole,
quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and
pyrazole.
The term "halogen" refers to fluoro, chloro, bromo or iodo.
In a first embodiment, the present invention provides a process for
preparing a taxane comprising the steps of (1) converting cephalomannine to a
primary
amine taxane intermediate having the structure:
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
AcO 0 OR
NHZ O A-i
p Z' Ph _ 3~ Olum.=.
bR O
HO Bzwherein R is at each occurrence independently selected from hydrogen and
a hydroxy-
protecting group, and (2) converting the taxane intermediate to paclitaxel or
docetaxel.
In a more specific embodiment, cephalomannine is converted to a
cephalomannine aziridine analogue having the structure:
0
Ac0 0 OR
NH O 10
= 7
N E AT
Ts ph 3' puw... 13 nnn
~bR O
HO Bz0\ Ac
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group, by substituting the double bond of the C-13 side chain of
cephalomannine with an aziridine ring. The cephalomannine aziridine analogue
is
subsequently hydrolyzed to give the primary amine taxane intermediate.
In an alternate more specific embodiment, cephalomannine is directly
hydrolyzed with formic acid to give the primary amine taxane intermediate.
In yet another alternate more specific einbodiinent, cephalomannine is
converted to the primary amine taxane intermdiate by nitrosation using sodium
nitrite in
AcOH:Ac2O or N204 in acetonitrile, followed by lithium hydroxide and 30%
hydrogen
peroxide hydrolysis and, then, Raney-Nickel reduction according to the
reaction
sequence:
11
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
0
AcO 0 OR
NH O ip
7
\ % ~
nll
Ph 3 0111= 13
~)R ~ O
HO BzO~ AcO~
1
0
AcO 0 OR
NNO O 10 7
= 2
Ph 3 OIU.= 13 =mlll
-bR O
HO Bz6 AcO
1
AcO 0 OR
NHNO 0 Ip
_ 7
/ % ~
Ph 3 Olu- 13 =Miil
aR 0
HO Bz6 AcO
1
AcO 0 OR
NH2 0 Ip
7
Ph 3 Olu= 13 =nni
iDR H 0
HO Bz AcO
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group.
In yet another alternate more specific embodiment, cephalomannine is
converted to a cephalomannine epoxide analogue having the structure:
0
Ac0 O OR
N_H O 10 ? 7
O c z,
PIi 3 ; Olpm=.. 13 mnn
tR H O
HO BzAc0
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group, which is then reacted with sodium azide in methanol at 65 C
to give a
cephalomannine azido alcohol analogue having the structure:
12
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
N3 O
Ac0 O OR
NH O 10
7
HO 2~
Ph 3 Olum-.. 13 nm
{)R O
HO BzO0 Ac
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group, which is then reduced to the give the primary amine taxane
intermediate.
In a second embodiment, the present invention provides a process for
preparing a taxane comprising the steps of (1) converting cinnamoyl halide to
a
cinnamoyl halide aziridine intermediate having the structure:
0
Ph
X
N
Ts
wherein X is halogen, (2) coupling the cinnamoyl halide aziridine intermediate
with
protected baccatin III using NaH, DCM to provide a protected baccatin III
aziridine
intermediate having the structure:
Ac0 O OR
Q 10
7
Ph
Qlllm.. 13 ..mull
N = Q
Ts H -
HO BzAc0
wherein R is selected from hydrogen and a hydroxy-protecting group, (3)
hydrolyzing
the protected baccatin III aziridine intermediate to a taxane intermediate
having the
structure:
AcO 0 OR
~ Z'
NH, O A-z-
Ph 3~
bAc O
HO Bzwherein R is selected from hydrogen and a hydroxy-protecting group, and
(4) converting the taxane intermediate to paclitaxel or docetaxel.
In a more specific embodiment of the foregoing process, X is chloro.
13
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
In a third embodiment, the present invention provides a process for
preparing a taxane comprising the steps of (1) converting cinnamoyl halide to
a
cinnamoyl halide aziridine intermediate having the structure:
0
Ph
X
N
Ts
wherein X is halogen, (2) reacting the cinnamoyl halide aziridine intermediate
with
acetic acid to give an open chain cinnamoyl halide intermediate having the
structure:
NHTs 0
Ph X
OAc
wherein X is halogen, (3) coupling the open chain cinnamoyl halide
intermediate with
protected baccatin III using NaH, DCM to provide a protected baccatin III
intermediate
having the structure:
Ac0 O OR
NHTs O 10
7
Ph Olum,.. 13 unn
OAc H , O
HO Bz0' Ac0
wherein R is selected from hydrogen and a hydroxy-protecting group, (4)
hydrolyzing
the protected baccatin III intermediate to a taxane intermediate having the
structure:
Ac0 O OR
NH, 0 10
= 7
Z
Ph 3 ; Oum,.. 13 nnt
bAc H 0
HO Bz0' Ac0
wherein R is selected from hydrogen and a hydroxy-protecting group, and (5)
converting the taxane intermediate to paclitaxel or docetaxel.
In a more specific embodiment of the foregoing process, the step of
reacting the open chain cinnamoyl halide intermediate with protected baccatin
III
further comprises the steps of (1) converting the open chain cinnamoyl halide
intermediate to a(3-lactam intermediate having the structure:
14
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
AcO Ph
gN
0 Ts
and (2) reacting the (3-lactam intermediate with protected baccatin III to
provide the
protected baccatin III intermediate.
In another more specific embodiment of the foregoing process, X is
chloro.
In a fourth embodiment, the present invention provides a process for
preparing docetaxel from cephalomannine by introduction of a t-BOC group at
the
secondary amine of protected cephalomannine followed by hydrolysis with
lithium
hydroxide in THF, and deprotection at the 2', 7 and 10 positions according to
the
reaction sequence:
O
Ac0 O OR
~ \Y NH O 10 '
zPh ;OU~~ i~ =~il
aR = H~ O
HO Bz(f AcO
I
O
Ac0 O OR
N,t-BOC O
10 7
Ph 'Olu= ~3 ==~nl
~DR AO' O
HO BzO~
I
AcO 0 OR
t-BOC-HN~ 0
to 7
Ph '' Olu= ~; ==~nl
~R = H~ O
HO BzO~ Ac0
0 1 HO O OH
t-BuO NH 0 10
Ph '- 0111'= iz ml
~ 0
HO BzO~ Ac0
wherein R is at each occurrence independently selected from hydrogen and a
hydroxy-
protecting group.
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
EXAMPLES
The following Examples disclose specific processes for synthesizing
various aziridine analogues, and their conversion to paclitaxel and docetaxel.
The
disclosed processes may be utilized with both purified and partially purified
taxanes.
Unless otherwise noted, all scientific and technical terms have the meanings
as
understood by one of ordinary skill in the art.
EXAMPLE 1
Aziridination of cephalomannine
As shown in Figure 1, cephalomannine (0.12 mmol) was dissolved in
dry freshly distilled acetonitrile (I ml) at room temperature under anhydrous
conditions.
To this solution was added chloroamine-T (0.18 mmol), followed by copper
triflate
(0.12 mmol) with vigorous stirring. The mixture was stirred under slightly
warming
(25 C) conditions until all starting material were consumed. The mixture was
worked
up and purified by column chromatography using mixtures of dichloromethane and
ethyl acetate to give white crystals of the cephalomannine aziridine analogue.
Preparation ofprimary amine taxane intermediate
Process 1. To a solution of the above cephalomannine aziridine
analogue (0.025 mmol) in dry benzene (5 ml) were added o-phenylenediamine
(0.025
mmol) and p-toluenesulfonic acid (catalytic, 2 ing). The mixture was refluxed
for 16 h
until all starting material was consumed (TLC). The mixture was allowed to
cool to
room temperature, diluted with ethyl acetate and washed successively with
dilute HCl
(1N) followed by water and brine. The organic layer was dried and purified by
column
chromatography using mixtures of dichloromethane and ethyl acetate to yield
the
primary amine taxane intermediate.
Process 2. To a 0.2 M solution of the above cephalomannine
aziridine analogue (3.51 mmol) in tetrahydrofuran was added 10.54 ml (10.54
mmol) of
a 1.0 N solution of lithium hydroxide. The solution was stirred for 12 h at
room
temperature. After removal of tetrahydrofuran in vacuo, the basic aqueous
residue was
acidified by the addition of 10% acetic acid and extracted with ether. Drying
(MgSO4)
and concentration afforded the crude material that was purified by column
chromatography to afford the pure white solid of the primary amine taxane
intermediate. (Note: The following could also be used: 10 equiv. LiOH, 20
equiv. 30%
H202, 3:1 THF:H20, time, 0=:>T C; Na2SO3, 5 min. 0 C).
16
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
Conversion of primary amine taxane intermediate to paclitaxel or docetaxel
A sample of the primary amine taxane intermediate (0.091 mmol) was
dissolved in ethyl acetate (9.1 ml) and a saturated solution of NaHCO3 (9.1
ml) was
added. To this biphasic mixture was added di-tert-butyl dicarbonate (0.18
mmol). The
mixture was stirred for 12 h at room temperature and TLC showed complete
consumption of the starting material. The reaction was worked up as usual and
the
residue purified by column chromatography using mixtures of diclzloromethane
and
ethyl acetate or acetone to give docetaxel. The 1H NMR, 13C NMR and mass
spectra
data for the isolated material match with the reported data for docetaxel.
To convert the primary amine to taxol, there are several methods that
could be used, such as the method disclosed in U.S. Patent No. 5,808,113,
which is
incorporated herein by reference in its entirety.
EXAMPLE 2
Hydrolysis of cephalomannine
As shown in Figure 2, cephalomannine was dissolved in formic acid at 0
C, stirred at this temperature for 12 h, poured over crushed ice and worked up
as usual.
The crude residue was purified by column chromatography using mixtures of
dichloromethane and ethyl acetate to afford the pure primary amine taxane
intermediate.
EXAMPLE 3
Aziridination of cinnamoyl chloride
As shown in Figure 3, to a mixture of cinnamoyl chloride and anhydrous
chloramine-T in acetonitrile was added pllenyltrimethylammonium tribromide
(PTAB)
at room temperature. After 12 h of vigorous stirring, the reaction mixture was
concentrated and filtered through a short column of silica gel and eluted with
10% ethyl
acetate in hexanes. After evaporation of the solvent, the resultant solid was
purified by
column chromatography or recrystallization to afford the cinnamoyl chloride
aziridine
intermediate.
Acid-catalyzed ring opening
As further shown in Figure 3, the cinnamoyl chloride aziridine
intermediate was dissolved in aqueous acetic acid at 0 C, stirred at this
temperature for
17
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
h and worked up as usual. Purification of the crude mixture by column
chromatography and crystallization afforded the open chain cinnamoyl chloride
intermediate.
PMaration of [3-lactam intermediate
5 As shown in Figure 4, the above open chain cinnamoyl chloride
intermediate was cyclized to form the (3-lactam intermediate using methods
well known
in the literature.
EXAMPLE 4
Coupling Reaction
10 As shown in Figure 5, the open chain cinnainoyl chloride intermediate
and C7 protected baccatin III were dissolved in anhydrous freshly distilled
THF under
argon atmosphere at room temperature. The stirred solution was cooled to 0 C
and
added to a suspension of NaH in THF at 0 C. The solution was warmed slowly to
room temperature and maintained at this temperature for 3 h. The reaction
mixture was
cooled to 0 C and quenched with brine. The reaction mixture was extracted with
dichloromethane and the combined extracts were washed several times with
brine, dried
over anhydrous sodium sulfate, and concentrated under reduced pressure to give
the
crude product. The crude product was purified by column chromatography using
mixtures of hexanes and ethyl acetate to afford the pure coupled protected
baccatin III
intermediate that could be hydrolyzed to give the primary amine taxane
intermediate.
Although this reaction is illustrated in Figure 5 with sodium hydride, in
other
embodiments of the present invention the coupling may be performed in the
presences
of a metal alkoxide, e.g., sodium hexamethyldisalide or lewis acid.
EXAMPLE 5
Nitrosation
As shown in Figure 6, to a solution of cephalomannine (0.76 mmol) in
glacial acetic acid (2.5 ml) and acetic anhydride (5 ml) at 0 C was added
NaNO2 (7.6
mmol). The resulting solution was stirred under argon at 0 C for 16 h and then
poured
over ice and extracted with diethyl ether. The combined organic extracts were
washed
with water, 5% NaZCO3, water and saturated NaCI and dried over MgSO4. The dry
extracts were filtered and then concentrated in vacuo, and the crude product
was
18
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
purified by column chromatography using mixtures of hexane-ethyl acetate to
afford
the pure product.
Hydrolysis
To the above solution in tetrahydrofuran was added a 1.0 N solution of
lithium hydroxide. The solution was stirred for 12 h at room temperature.
After
removal of tetrahydrofuran in vacuo, the basic aqueous residue was acidified
by the
addition of 10% acetic acid and extracted with ether. Drying (MgSO4) and
concentration afforded the crude material that was purified by column
chromatography
to afford the pure white solid of the primary amine taxane intermediate.
(Note: The
following could also be used: 10 equiv. LiOH, 20 equiv. 30% H202, 3=:1
THF:H20,
time, 0=>T C; Na2SO3, 5 min. 0 C).
Reduction
The above hydrolyzed product was dissolved in ethanol at room
temperature and Raney-Nickel was added in one portion to the stirred solution.
The
reaction mixture was stirred at this temperature and treated with hydrogen,
until the
complete consumption of the starting material. The reaction mixture was
filtered and
the filtrate evaporated. The residue was dissolved in an inert solvent such as
dichloromethane and worked up as usual. The crude product was purified by
column
chromatography using mixtures of dichloromethane and ethyl acetate to afford
the pure
product.
EXAMPLE 6
Preparation of N-acyl derivative
As shown in Figure 7, to a solution of cephalomannine (9.47 mmol) in
dichloromethane was added triethylamine (9.47 mmol), di-tert-butyl dicarbonate
(18.94
mmol), and 4-(dimethylamino)pyridine (DMAP) (9.47 mmol). The solution was
stirred
for 12 h at room temperature under an argon atmosphere. The volatiles were
removed
and the residue was purified by colunm chromatography. Elution with
dichloromethane
and ethyl acetate afforded the cephalomannine N-t-BOC derivative.
Alternatively, DMAP (0.1 mmol) was added to a stirred solution of the
cephalomannine (1.0 mmol) in dry acetonitrile followed by BOC2O (1.1 mmol).
After
stirring for 10 h at room temperature, all starting material was consumed
(TLC). The
reaction mixture was evaporated at room temperature and the residue
partitioned
19
CA 02598707 2007-08-22
WO 2005/082875 PCT/US2005/005953
between ether and aqueous KHSO4. The organic extract was thoroughly washed in
turn
with aqueous solution of KHSO4 and NaHCO3 and finally brine and dried over
MgSO4.
Evaporation to complete dryness left a light yellow residue that was purified
by column
chromatography to afford the cepahlomannine N-t-BOC derivative.
EXAMPLE 7
Preparation of cephalomannine epoxide analogue
As shown in Figure 8, to a solution of cephalomannine in
dichloromethane was added NaHCO3 followed by MCPBA at -15 C. The reaction was
worked up as usual after the consumption of the starting material and purified
by
column chromatography using mixtures of dichloromethane and ethyl acetate to
afford
the pure cephalomannine epoxide analogue.
Preparation of cephalomannnine azido alcohol analogue
The cephalomannine epoxide analogue was dissolved in methanol and
aqueous solution of NaN3 was added at room temperature. The solution was
heated to
65 C for 12 h. The reaction mixture was cooled to room temperature and worked
up as
usual and purified by column chromatography using mixtures of dichloromethane
and
ethyl acetate to afford the pure cephalomannine azido alcohol analogue.
All of the above U.S. patents, U.S. patent application publications, U.S.
patent applications, foreign patents, foreign patent applications and non-
patent
publications referred to in this specification and/or listed in the
Application Data Sheet,
are incorporated herein by reference, in their entirety.
From the foregoing it will be appreciated that, although specific
einbodiments of the invention have been described herein for purposes of
illustration,
various modifications may be made without deviating from the spirit and scope
of the
invention. Accordingly, the invention is not limited except as by the appended
claims.
